Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

236 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lapatinib for breast cancer: a review of the current literature.
MacFarlane RJ, Gelmon KA. MacFarlane RJ, et al. Among authors: gelmon ka. Expert Opin Drug Saf. 2011 Jan;10(1):109-21. doi: 10.1517/14740338.2011.533168. Epub 2010 Nov 20. Expert Opin Drug Saf. 2011. PMID: 21091041 Review.
Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers.
Waterhouse DN, Gelmon KA, Klasa R, Chi K, Huntsman D, Ramsay E, Wasan E, Edwards L, Tucker C, Zastre J, Wang YZ, Yapp D, Dragowska W, Dunn S, Dedhar S, Bally MB. Waterhouse DN, et al. Among authors: gelmon ka. Curr Cancer Drug Targets. 2006 Sep;6(6):455-89. doi: 10.2174/156800906778194586. Curr Cancer Drug Targets. 2006. PMID: 17017873 Review.
Breast carcinoma--rare types: review of the literature.
Yerushalmi R, Hayes MM, Gelmon KA. Yerushalmi R, et al. Among authors: gelmon ka. Ann Oncol. 2009 Nov;20(11):1763-70. doi: 10.1093/annonc/mdp245. Epub 2009 Jul 14. Ann Oncol. 2009. PMID: 19602565 Free article. Review.
Ki67 in breast cancer: prognostic and predictive potential.
Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Yerushalmi R, et al. Among authors: gelmon ka. Lancet Oncol. 2010 Feb;11(2):174-83. doi: 10.1016/S1470-2045(09)70262-1. Lancet Oncol. 2010. PMID: 20152769 Review.
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A. Gelmon KA, et al. Lancet Oncol. 2011 Sep;12(9):852-61. doi: 10.1016/S1470-2045(11)70214-5. Epub 2011 Aug 19. Lancet Oncol. 2011. PMID: 21862407 Clinical Trial.
236 results